Literature DB >> 1901463

Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator.

B J Anderson1, S R Keeley, N D Johnson.   

Abstract

Four neonates suffered caval thrombosis secondary to indwelling central catheters. Dissolution of thrombus with recombinant tissue plasminogen activator (rt-PA) as a low-dose infusion (0.05 mg/kg/hr) directly into thrombus was successful in three patients. rt-PA was ceased after three days in the fourth patient because of catheter malposition. Thrombolysis was achieved between four and ten days. Rethrombosis occurred in one patient despite heparin prophylaxis. Plasminogen activator infusions were titrated to maintain fibrinogen levels above 100 mg/dl. One neonate suffered an intracranial haemorrhage. Regional rt-PA is an alternative to thrombectomy in critically ill neonates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901463     DOI: 10.1177/0310057X9101900104

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  10 in total

1.  Successful treatment of superior vena cava thrombosis in a neonate.

Authors:  Stephan Gerling; Jens Klinge; Helmut Singer; Michael Hofbeck
Journal:  Eur J Pediatr       Date:  2002-08       Impact factor: 3.183

2.  Thrombolysis with low dose tissue plasminogen activator.

Authors:  E Doyle; J Britto; J Freeman; F Munro; N S Morton
Journal:  Arch Dis Child       Date:  1992-12       Impact factor: 3.791

3.  Pulse-spray thrombolysis of inferior vena cava thrombosis complicating filter placement.

Authors:  M E Hansen; G L Miller; K C Starks
Journal:  Cardiovasc Intervent Radiol       Date:  1994 Jan-Feb       Impact factor: 2.740

Review 4.  Pediatric interventional radiology: current practice and innovations.

Authors:  A M Hubbard; K E Fellows
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Sep-Oct       Impact factor: 2.740

Review 5.  Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature.

Authors:  J Hartmann; A Hussein; E Trowitzsch; J Becker; K H Hennecke
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-07       Impact factor: 5.747

Review 6.  Management of preterm infants with intracardiac thrombi: use of thrombolytic agents.

Authors:  P C Rimensberger; J R Humbert; M Beghetti
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

7.  Clinical experience with alteplase in the management of intracardiac and major cardiac vessels thrombosis in pediatrics: a case series.

Authors:  Abdulrazaq S Al-Jazairi; Roaa A Al-Gain; Zead R Bulbul; Antoine J Cherfan
Journal:  Ann Saudi Med       Date:  2010 May-Jun       Impact factor: 1.526

8.  Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children.

Authors:  W Zenz; W Muntean; A Beitzke; G Zobel; M Riccabona; A Gamillscheg
Journal:  Br Heart J       Date:  1993-10

Review 9.  Thrombolytic agents for arterial and venous thromboses in neonates.

Authors:  C M John; C Harkensee
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

Review 10.  Thrombosis in the critically ill neonate: incidence, diagnosis, and management.

Authors:  Alex Veldman; Marcel F Nold; Ina Michel-Behnke
Journal:  Vasc Health Risk Manag       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.